Dr Mehdi Touat
- Spécialité
- Neuro-oncologue, expert tumeurs cérébrales primitives de l'adulte
- Hôpital
- Hôpital Pitié Salpétrière (Paris), APHP, Sorbonne Université, Institut du Cerveau
- Derniers articles
-
- 18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors. (2 févr. 2026)
- RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma. (8 janv. 2026)
- Dramatic response to entrectinib in a rare glioneuronal tumor harboring an NTRK2 fusion. (27 déc. 2025)
- Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. (1 déc. 2025)
- Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. (9 oct. 2025)